A Real-world Study Of Shenqi Shenshui Mixture Delaying The Progression Of Renal Function In Chronic Kidney Disease

Objective:Based on real-world research methods,a retrospective study was conducted to analyze the clinical efficacy and safety of Shenqi Shenshuai mixture in treating chronic kidney disease and delaying the progression of renal function in chronic kidney disease,so as to provide theoretical basis for the treatment of chronic kidney disease.Methods:According to the inclusion and exclusion criteria,the patients who were treated with Shenqi Shenshuai mixture in the Department of Nephrology of Wuhan NO.1 Hospital from October 2018to September 2021 were selected,and the changes in e GFR were used to reflect the clinical efficacy of Shenqi Shenshuai Mixture;logistic regression model was used to analyze whether gender,age,hypertension,diabetes and anemia were independent factors affecting the efficacy of Shenqi Shenshuai mixture in the treatment of chronic kidney disease;the safety of Shenqi Shenshuai mixture in clinical treatment was evaluated from blood biochemical indexes.Results:A total of 1088 patients were included in this study,including 722（66.36%）males and 366（33.64%）females.The overall average age was（61.74±12.45）years,the average age of males was（61.00±12.39）years,and the average age of females was（63.19±12.46）years.630（57.90%）patients with hypertension,406（64.44%）males,224（35.56%）females,313（28.77%）patients with diabetes,and 226（72.20%）males,87（27.80%）female;The average annual decline rate of e GFR in 1088 patients who used Shenqi Shenshuai Mixture was 0.33±14.30 ml/（min·1.73m~2）,and the average annual decline rate of e GFR was-0.37±14.98 ml/（min·1.73m~2）for male patients,The average annual decline rate of e GFR was 1.72±12.73ml/（min·1.73m~2）for female patients,suggesting that Shenqi Shenshuai Mixture can delay the decline of e GFR in CKD patients,and may be better in male patients than in female patients;Elderly CKD patients,aged between 65 and 80 years old,the average annual decline rate of e GFR after treatment was-0.65±14.40ml/（min·1.73m~2）,and the average annual decline rate of e GFR after treatment for patients older than 80 years was 1.02±10.54ml/（min·1.73m~2）,suggesting that Shenqi Shenshuai Mixture could help to delay the decline of e GFR in elderly patients with CKD;In CKD patients without hypertension,the average annual decline rate of e GFR after treatment was-1.64±14.70 ml/（min·1.73m~2）,and in CKD patients with hypertension,the average annual decline rate of e GFR was 1.77±13.83 ml/（min·1.73m~2）,suggesting that Shenqi Shenshuai Mixture may delay the decline of e GFR in hypertensive CKD patients;In CKD patients without diabetes,the average annual decline rate of e GFR after treatment was 0.02±14.25ml/（min·1.73m~2）,and the average annual decline rate of e GFR in CKD patients with diabetes was 1.10±14.40 ml/（min·1.73m~2）,suggesting that Shenqi Shenshuai Mixture may delay the decline of e GFR in diabetic CKD patients;In CKD patients without anemia,the average annual decline rate of e GFR after treatment was-0.10±14.27 ml/（min·1.73m~2）,and in CKD patients with anemia degree of90-110 g/L,the average annual decline rate of e GFR after treatment was 3.24±12.40 ml/（min·1.73m~2）,CKD patients with anemia degree of 60～90 g/L,the average annual decline rate of e GFR after treatment was 1.13±13.09 ml/（min·1.73m~2）,suggesting that Shenqi Shenshuai Mixture may have better curative effect on CKD patients without anemia;In CKD patients with CKD stage of 30-60ml/（min·1.73m~2）,the average annual decline rate of e GFR after treatment was-1.21±15.25 ml/（min·1.73m~2）,suggesting that Shenqi Shenshuai Mixture has better curative effect on patients with CKD stage 3;Multivariate logistic regression analysis showed that gender,age,and hypertension were the independent influencing factors for the efficacy of Shenqi Shenshuai Mixture in the treatment of chronic kidney disease,while diabetes and anemia were not independent influencing factors for the efficacy of Shenqi Shenshuai Mixture in the treatment of chronic kidney disease;The results of the safety evaluation indicated that the traditional Chinese medicine Shenqi Shenshui Mixture had no significant effect on liver function and serum potassium,and it was considered that its clinical safety was good.Conclusion:Shenqi Shenshuai Mixture can help to delay the decline of renal function in patients with CKD and protect the residual renal function.It was effective in both elderly CKD patients and CKD patients with hypertension or diabetes.At the same time,it had good safety and was worthy of clinical promotion.